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ABSTRACT
Objectives: A growing body of evidence suggests that
there is a relationship between impaired lung function
and the risk of developing diabetes mellitus (DM).
However, it is not known if this reflects a causal effect of
lung function on glucose metabolism. To clarify the
relationship between lung function and the development
of DM, we examined the incidence of newly diagnosed
prediabetes (a precursor of DM) among subjects with
normal glucose tolerance (NGT) at baseline.
Design: Primary analysis of an occupational cohort with
both cross-sectional and longitudinal data (follow-up
duration mean±SD: 28.4±6.1 months).
Setting and participants: Data were analysed from
1058 men in a cross-sectional study and from 560 men
with NGT in a longitudinal study.
Outcomes and methods: Impaired lung function (per
cent predicted value of forced vital capacity (%FVC) or
per cent value of forced expiratory volume 1 s/FVC
(FEV1/FVC ratio)) in relation to the ratio of prediabetes or
DM in a cross-sectional study and development of new
prediabetes in a longitudinal study. NGT, prediabetes
including impaired glucose tolerance (IGT) and increased
fasting glucose (IFG) and DM were diagnosed according
to 75 g oral glucose tolerance tests.
Measurements and main results:%FVC at baseline,
but not FEV1/FVC ratio at baseline, was significantly
associated with the incidences of DM and prediabetes.
Among prediabetes, IGT but not IFG was associated with
%FVC. During follow-up, 102 subjects developed
prediabetes among those with NGT. A low %FVC, but not
FEV1/FVC ratio, was predictive of an increased risk for
development of IGT, but not of IFG.
Conclusions: Low lung volume is associated with an
increased risk for the development of prediabetes,
especially IGT, in Japanese men. Although there is
published evidence for an association between chronic
obstructive pulmonary disease and DM, prediabetes is
not associated with the early stage of COPD.
INTRODUCTION
Accumulating evidence suggests that there is
a close relationship between impaired lung
function and diabetes mellitus (DM).
Population-based studies have demonstrated
associations between both obstructive and
restrictive lung impairment and insulin resist-
ance or DM.1–9 A representative obstructive
lung disease, chronic obstructive pulmonary
disease (COPD), is now well known to be
associated with a variety of comorbidities,
including DM.10–13 However, an accelerated
decline of lung function has been observed
in patients with DM.14 The incidence rates of
COPD, asthma, lung fibrosis and pneumonia
ARTICLE SUMMARY
Article focus
▪ We hypothesised that lung function is associated
with the development of impaired glucose
metabolism. To investigate this, the data of an
occupational cohort were analysed from 1058
men in a cross-sectional study and from 560
men with normal glucose tolerance (NGT) in a
longitudinal study.
Key messages
▪ Low lung volume was significantly associated
with the incidence of prediabetes or diabetes
mellitus (DM) in both cross-sectional and longi-
tudinal studies.
▪ Low lung volume is an independent risk factor
for a particular type of prediabetes, impaired
glucose tolerance rather than impaired fasting
glucose. Our results suggested that prediabetes
is not associated with the early stage of COPD,
although there are published evidences for an
association between COPD and DM.
Strengths and limitations of this study
▪ This is the first study that prospectively exam-
ined the incidence of newly diagnosed predia-
betes among subjects with NGT at baseline.
There are several limitations including that the
subjects were limited to Japanese men and our
occupational cohort may possibly be healthier
than the general population.
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are greater in patients with DM than in those without
DM.15 The incidence of death from COPD is also
increased in DM.16
The metabolic stage between normal glucose homeo-
stasis and DM is called prediabetes, which the WHO
divides into impaired glucose tolerance (IGT) and
increased fasting glucose (IFG).17 Both IFG and IGT are
the established risk factors for DM.18 The Diabetes
Prevention Program Research Group15 found that about
30% of subjects with prediabetes developed DM during
3–5 years of follow-up. IFG and IGT are also risk factors
for cardiovascular disease (CVD), relationships that are
not confounded by the development of DM.19 20
Subjects with prediabetes also have higher incidence
rates of microvascular complications, including neur-
opathy, retinopathy and nephropathy, than do those
with normal glucose tolerance (NGT).21 22
We reported previously that smokers with airflow
limitation had subclinical atherosclerosis as evidenced
by carotid intima-media thickness (CIMT).12 Although
we excluded subjects with DM, the prediabetic state
may influence the association, since prediabetes per
se was accompanied by a modest but significant
increase in the risk for developing CVD, as described
above. However, there is no information regarding
the association between lung function and predia-
betes. Therefore, we explored the incidence of newly
diagnosed prediabetes among selected subjects with
NGT to further elucidate the nature of the relation-
ship between lung function and the development
of DM.
METHODS
Subjects
The subjects were recruited from 1218 men who attended
the Nippon Telegraph and Telephone West Corporation
Chugoku Health Administration Center for general health
checkups between April 1999 and March 2006. One
hundred and sixty subjects were excluded, because they
did not meet the following inclusion criteria: (1) between
40 and 59 years of age at the first examination, and able to
perform both a 75 g oral glucose tolerance test (OGTT)
and adequate spirometric measurements (146 subjects
excluded); (2) no known respiratory disease (14
excluded). Data from the remaining 1058 subjects were
used for a baseline cross-sectional analysis. For the longitu-
dinal study, subjects were restricted to those who had NGT
(365 excluded), and could be followed up for more than
20 months (133 excluded). The remaining 560 subjects
were included. Among these subjects, 77 were receiving
medication for hypertension, 43 for dyslipidaemia and 11
for hyperuricaemia. The distributions of these subjects
among the quartiles of percent predicted value of %FVC
and percent value of 1 s/FVC (FEV1/FVC ratio) were not
significantly different.
The study was approved by the Ethical Committee of
Kochi University.
75 g oral glucose tolerance test
DM and prediabetes were diagnosed according to the
2003 criteria of the WHO.17 Subjects with prediabetes
were classified into two categories: isolated IFG and IGT.
Isolated IFG was defined as a fasting plasma glucose
level of 6.1–6.9 mmol/l and a 2 h postload plasma
glucose level of <7.8 mmol/l; and IGT was defined by a
fasting plasma glucose level of <7.0 mmol/l and a 2 h
postload plasma glucose level of 7.8–11.1 mmol/l. Blood
samples were collected after a 10 h fast, and then 2 h
after a 75 g oral glucose load.
Fasting insulin was measured by an enzyme immunoassay
(Dainabot, Tokyo, Japan) with an intra-assay coefficient of
variation of 3.1–4.4%. The homeostasis model assessment
(HOMA) formula, (fasting insulin (mU/l)×fasting glucose
(mmol/l))/22.5, was used to calculate the insulin resist-
ance score.
Pulmonary function test
Pulmonary function was measured using a spirometer
(Chest HI-801; Chest Co., Tokyo, Japan) by an experi-
enced technician according to the recommendations of
the American Thoracic Society.23 The Japanese refer-
ence values were used.24
Statistical analysis
Statistical analysis was carried out using SPSS, V.18.0 (SPSS
Japan Inc, Tokyo, Japan). Statistical comparisons of the
baseline characteristics of each group were performed
using either the χ-square test or one-way analysis of vari-
ance (ANOVA). Comparisons among the groups were per-
formed by using post-hoc Tukey test. In the cross-sectional
study, logistic regression models were used to estimate the
relevant ORs. In the longitudinal study, the HR of each
covariate for the risk of development of prediabetes with
95% CI was calculated using the Cox hazard model. Tests
for a linear trend across increasing categories of spiro-
metric indices were conducted by treating the categories
as continuous variables in a model. In all analyses, p<0.05
was taken to indicate statistical significance.
RESULTS
Baseline analysis
At baseline, our study population (n=1058) consisted of
693 normal subjects, 93 with isolated IFG, 167 with IGT
and 105 with DM. To examine the relationship between
lung function parameters and impaired glucose metab-
olism, the subjects were divided into quartiles according
to baseline %FVC and the FEV1/FVC ratio. Some para-
meters, including age, body mass index (BMI), systolic
blood pressure and total cholesterol, differed signifi-
cantly among the quartiles (table 1). After adjustment
for these parameters, impaired glucose metabolism was
significantly associated with %FVC (p<0.001), but not
with the FEV1/FVC ratio (p=0.80). Specifically, IGT
(p=0.04) and DM (p=0.008), but not isolated IFG
(p=0.28), were associated with %FVC (table 2).
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Frequencies of newly diagnosed prediabetes in subjects
with NGT
After the observation period (mean±SD: 28.4
±6.1 months), there were 44 subjects with isolated IFG
and 58 with IGT among those previously categorised
as NGT (n=560), but no subject developed DM. As
shown in table 3, there were significant differences in
several parameters at baseline, including height, BMI,
systolic blood pressure and %FVC, but not in FEV1/
FVC ratio.
Table 2 ORs*(95% CI) of prediabetes and DM according to the quartiles of %FVC† or FEV1%‡ in the cross-sectional
study
I II III IV p for trend
IFG
%FVC 1.0 4.60 (1.29 to 16.39) 2.03 (0.53 to 7.79) 2.57 (0.69 to 9.60) 0.06
FEV1/FVC 1.0 1.00 (0.32 to 3.12) 1.39 (0.49 to 3.93) 1.81 (0.67 to 4.90) 0.53
IGT
%FVC 1.0 1.35 (0.57 to 3.19) 2.18 (1.02 to 4.05) 2.59 (1.17 to 5.69) 0.04
FEV1/FVC 1.0 0.60 (0.35 to 1.15) 0.62 (0.37 to 1.16) 0.50 (0.30 to 1.02) 0.12
IFG or IGT
%FVC 1.0 2.18 (1.08 to 4.42) 2.09 (1.04 to 4.18) 2.55 (1.28 to 5.09) <0.001
FEV1/FVC 1.0 0.56 (0.31 to 1.07) 0.63 (0.35 to 1.14) 0.65 (0.36 to 1.17) 0.29
DM
%FVC 1.0 3.77 (1.29 to 11.03) 1.28 (0.41 to 3.99) 2.50 (0.87 to 7.16) 0.02
FEV1/FVC 1.0 2.08 (0.72 to 5.99) 3.05 (1.12 to 8.31) 2.13 (0.76 to 6.00) 0.18
IFG or IGT, or DM
%FVC 1.0 3.32 (1.71 to 6.42) 2.04 (1.06 to 3.94) 3.33 (1.74 to 6.38) <0.001
FEV1/FVC 1.0 0.74 (0.40 to 1.35) 0.98 (0.56 to 1.75) 0.84 (0.48 to 1.49) 0.70
*OR was adjusted for age, BMI, pack-year smoking, systolic BP and T-chol.
†%FVC quartile; I (highest group) (≥104.2%), II (96.0%≤%FVC<104.2%), III (86.4%≤%FVC<96.0%), IV (lowest group) (%FVC<86.4%).
‡FEV1/FVC quartile; I (highest group) (≥85.0), II (81.1%≤FEV1/FVC<85.0%), III (76.5%≤FEV1/FVC<81.1%), IV (lowest group)
(FEV1/FVC<76.5%).
BMI, body mass index; BP, blood pressure; DM, diabetes mellitus; IFG, impaired fasting glucose; IFG, increased fasting glucose;
IGT, impaired glucose tolerance; T-chol, total cholesterol.
Table 1 Baseline characteristics of subjects with NGT, isolated IFG, IGT and DM in the cross-sectional study
NGT Isolated IFG IGT DM p Value
Number of subjects 693 93 167 105
Current smokers (%) 48 42 45 50 0.54
Age (years) 49.5±5.5 50.9±5.3* 51.1±5.3** 52.2±4.7*** <0.001
Height (cm) 169.9±5.7 168.8±5.8 169.1±6.0 168.4±5.0* 0.03
BMI (kg/m2) 23.1±2.5 23.9±3.1** 24.6±2.8*** 24.8±3.2*** <0.001
Systolic BP (mm Hg) 126.4±16.3 135.1±16.4*** 135.9±18.2*** 140.2±16.3*** <0.001
Pack-year smoking 30.5±15.6 38.0±22.6* 31.1±17.3 38.0±18.5** 0.002
FEV1/FVC (%) 80.1±7.0 79.6±7.8 80.9±7.4 79.4±8.5 0.36
%FVC 97.9±14.2 96.5±12.9 92.0±13.3*** 89.2±15.7*** <0.001
Fasting glucose (mmol/l) 5.3±0.4 6.3±0.2*** 5.9±0.5*** 8.1±1.6*** <0.001
120 min glucose (mmol/l) 5.7±1.0 6.5±0.8*** 8.8±0.8*** 12.4±4.0*** <0.001
HbA1c (%) 5.10±0.33 5.34±0.36*** 5.37±0.41*** 6.57±1.20*** <0.001
HOMA-R 1.08±0.56 1.91±2.23** 1.56±0.88*** 2.33±1.41*** <0.001
C reactive protein (mg/l) 0.11±0.29 0.09±0.14 0.14±0.28 0.18±0.46 0.13
T-chol (mg/dl) 202.1±32.6 210.0±28.7* 209.5±36.3* 214.8±32.2*** <0.001
Values are numbers, percentages (%) or means ±SD.
*p<0.05.
**p<0.01.
***p<0.001 vs NGT.
BMI, body mass index; BP, blood pressure; CRP, C reactive protein; DM, diabetes mellitus; HbA1c, glycated haemoglobin; HOMA-R,
homeostasis model assessment of insulin resistance; IFG, increased fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose
tolerance; T-chol, total cholesterol.
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Lung function parameters were divided into quartiles
according to baseline %FVC and the FEV1/FVC ratios.
Among the quartiles the parameters, including age, BMI
and systolic blood pressure, were significantly different
(data not shown). Both in the crude model and following
adjustment by age, BMI, pack-year smoking and systolic
blood pressure, the development of prediabetes occurred
significantly more frequently in the lowest quartile of %
FVC, but not in that of the FEV1/FVC ratio (table 4).
Among prediabetes, IGT, but not isolated IFG, was signifi-
cantly associated with %FVC, as in the baseline cross-
sectional analysis (table 4; figure 1).
DISCUSSION
In the baseline cross-sectional study, we found that a low
%FVC, but not a low FEV1/FVC ratio, was significantly
associated with increased prevalences of prediabetes and
DM. As lung function might be impaired by DM, a
causal effect of lung function on DM could not be estab-
lished by these data. Therefore, we also explored pro-
spectively the effect of lung function on the
development of newly diagnosed prediabetes in the
population with normal glucose metabolism, as evi-
denced by the results of an OGTT. We found that
reduced lung volume (%FVC), but not airflow limitation
(FEV1/FVC ratio), was significantly associated with the
future development of prediabetes.
This study demonstrated that IGT, but not IFG, was
closely associated with lower lung volume in both cross-
sectional and longitudinal settings. Our finding was
supported by previous studies conducted in an Asian
population with relatively low BMI but high smoking
Figure 1 Incidences of newly
diagnosed prediabetes, isolated
IFG and impaired glucose
tolerance (IGT) according to
quartiles of % FVC and the
FEV1/FVC ratio. The incidence of
prediabetes was significantly
associated with %FVC, but not
with the FEV1/FVC ratio (p=0.01).
Among subjects with prediabetes,
lower %FVC was significantly
associated with a higher
incidence of IGT (p=0.04), but not
of IFG (p=0.47).
Table 3 Baseline characteristics of subjects who remained NGT, developed isolated IFG and IGT in the longitudinal study.
NGT Isolated IFG IGT p Value
Number of subjects 458 44 58
Current smokers (%) 48 30* 50 0.05
Age (years) 49.3±5.7 50.2±4.4 50.5±4.9 0.14
Height (cm) 169.9±5.6 170.2±4.9 167.1±6.7** 0.01
BMI (kg/m2) 23.0±2.5 23.8±2.3* 23.7±3.0* 0.04
Systolic BP (mm Hg) 125.4±16.7 130.5±16.9* 129.3±14.5 0.048
Pack-year smoking 29.9±15.6 31.1±12.1 30.1±18.5 0.97
FEV1/FVC (%) 80.1±7.1 79.7±6.3 79.9±7.9 0.95
%FVC (%) 97.5±14.2 93.0±14.7* 90.0±16.0*** <0.001
Fasting glucose (mmol/l) 5.3±0.4 5.6±0.2*** 5.5±0.3** <0.001
120 min glucose (mmol/l) 5.6±0.9 6.0±1.2 6.4±0.9*** <0.001
HbA1c (%) 5.07±0.33 5.31±0.37*** 5.19±0.30* <0.001
HOMA-R 1.04±0.53 1.19±0.61 1.31±0.64** 0.001
C reactive protein (mg/l) 0.10±0.23 0.18±0.42 0.16±0.30 0.26
T-chol (mg/dl) 201.4±34.5 205.3±27.1 212.5±28.6* 0.05
Duration (month) 28.6±6.2 28.5±5.1 27.6±5.6 0.13
Values are number, percentage (%) or mean±SD.
*p < 0.05.
**p<0.01.
***p<0.001 vs NGT.
BMI, body mass index; BP, blood pressure; CRP, C reactive protein; HOMA-R, homeostasis model assessment of insulin resistance;
IFG, increased fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; T-chol, total cholesterol.
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prevalence.8 9 In addition, such association between
lower lung function and impaired glucose metabolism
was also demonstrated in Western populations with
higher BMI but lower smoking prevalence, and the asso-
ciation had been shown to be independent of smoking
or obesity (refs. 1–6, for review ref. 7).
The mechanisms for the association are not clarified
at present. It has been suggested that IGT is caused
mainly by insulin resistance in the muscle, and IFG
mainly by insulin resistance in the liver.25 Reduced
lung volume is associated with reduced maximum
oxygen uptake, which may lead to poorer physical
fitness and physical activity, and thus result in insulin
resistance and DM.26–28 This may explain why IGT is
more closely associated with lung volume. Furthermore,
poorer lung function in adulthood may be due to low
birth weight or early-life malnutrition,29 30 both of
which have been reported to be associated with the
development of diabetes.31 Malnutrition as a neonate
may be an important early cause of cardiac and meta-
bolic disorders in adulthood as a consequence of fetal
programming.32 33
This study had several limitations. The study popula-
tion was limited to men, owing to the fact that sufficient
female subjects were not available at the institute. The
occupational cohort used in this study may not be repre-
sentative of Japanese men in general. For example, the
prevalence rates of hypertension and hyperlipidaemia in
this cohort were 13% and 7%, respectively (data not
shown). The National Health and Nutrition
Examination Survey in Japan showed prevalence rate of
these in general Japanese men aged 40–60 years, in
general, were around 30% and 35%, respectively, sug-
gesting that our occupational cohort may be healthier.
Subjects taking medications, including simvastatin,
which have been shown to lower the risk of impaired
glucose metabolism were not excluded, although the dis-
tributions of %FVC and the FEV1/FVC ratio in those
taking drugs for hypertension, dyslipidaemia and hyper-
uricaemia were not significantly different from those of
subjects not on such medication.
In conclusion, this study provides evidence for a pro-
spective relationship between lung volume and the inci-
dence of newly diagnosed prediabetes among subjects
with normal glucose metabolism at baseline. Among sub-
jects with prediabetes, the study also suggests that lung
volume may be a risk factor for the development of IGT,
which is mainly caused by insulin resistance in the
Table 4 HRs (95% CI) for development of isolated IFG or IGT according to the quartiles of %FVC*or FEV1%†
I II III IV p for trend
IFG
%FVC
Model 1 1.0 0.85 (0.38 to 1.92) 0.81 (0.36 to 1.79 1.96 (0.71 to 5.26) 0.31
Model 2 1.0 1.07 (0.48 to 2.39) 1.35 (0.60 to 3.03) 0.54 (0.20 to 1.49) 0.32
FEV1/FVC
Model 1 1.0 0.96 (0.42 to 2.17) 1.20 (0.51 to 2.86) 0.98 (0.43 to 2.27) 0.95
Model 2 1.0 0.99 (0.43 to 2.31) 0.84 (0.35 to 2.00) 1.04 (0.45 to 2.47) 0.96
IGT
%FVC
Model 1 1.0 1.96 (1.00 to 3.85) 2.63 (1.27 to 5.56) 3.03 (1.43 to 6.67) 0.006
Model 2 1.0 2.22 (1.02 to 3.88) 2.26 (1.07 to 4.78) 2.74 (1.26 to 5.98) 0.02
FEV1/FVC
Model 1 1.0 2.13 (0.96 to 4.76) 1.67 (0.81 to 3.45) 1.03 (0.54 to 1.96) 0.15
Model 2 1.0 2.09 (0.92 to 4.72) 1.69 (0.81 to 3.52) 1.11 (0.57 to 2.16) 0.10
IFG or IGT
%FVC
Model 1 1.0 2.13 (0.93 to 3.03) 1.85 (1.03 to 3.57) 2.63 (1.43 to 4.76) 0.01
Model 2 1.0 1.48 (0.89 to 2.44) 1.38 (0.82 to 2.34) 2.40 (1.30 to 4.44) 0.04
FEV1/FVC
Model 1 1.0 1.47 (0.84 to 2.56) 1.47 (0.85 to 2.56) 1.01 (0.61 to 1.69) 0.32
Model 2 1.0 1.47 (0.83 to 2.61) 1.47 (0.84 to 2.56) 1.09 (0.64 to 1.84) 0.21
*%FVC quartile; I (highest group) (≥106.0%), II (96.6%≤%FVC<106.0%) III (88.1%≤%FVC<96.6%), IV (lowest group) (%FVC<88.1%).
†FEV1/FVC quartile; I (highest group) (≥85.0%), II (80.9%≤FEV1/FVC<85.0%), III (76.0%≤FEV1/FVC<80.9%), IV (lowest group)
(FEV1/FVC<76.0%).
IGT, impaired glucose tolerance; IFG, increased fasting glucose.
Model 1 denotes crude model and model 2, adjusted for age, BMI, pack-year smoking and systolic BP.
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muscle, but not IFG, which is caused mainly by insulin
resistance in the liver. Although there is published evi-
dence for an association between COPD and DM, our
results suggest that prediabetes is not associated with at
least the early stage of COPD.
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